Akebia Therapeutics, Inc. (AX9.F)

1,1800 +0,0300 (+2,61%) Ab 08:06AM CEST. Markt geöffnet.

Akebia Therapeutics, Inc.

245 First Street
Suite 1400
Cambridge, MA 02142
United States
617 871 2098
https://www.akebia.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 167

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. John P. Butler MBA	CEO, President, Interim Principal Financial Officer & Director	1,69M	N/A	1964
Mr. Michel Dahan	Senior VP & COO	951,14k	N/A	1979
Ms. Nicole R. Hadas J.D.	Senior VP, Chief Legal Officer & Secretary	870,83k	N/A	1973
Dr. Steven Keith Burke M.D.	Senior VP of Research & Development and Chief Medical Officer	874,64k	N/A	1961
Mr. Richard C. Malabre	Chief Accounting Officer	N/A	N/A	1961
Ms. Kimberly Garko	Senior VP & Chief Technical Officer	N/A	N/A	N/A
Tracey Vetterick	Vice President of Portfolio Strategy & Corporate Administration	N/A	N/A	N/A
Mercedes Carrasco	Senior Director of Investor & Corporate Communications	N/A	N/A	N/A
Ms. Meredith Bowman	Senior VP & Chief People Officer	N/A	N/A	N/A
Ms. Carolyn Rucci	Senior Vice President of Legal & General Counsel	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Akebia Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 9, Vorstand: 6, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.